{"title":"Artificial intelligence and machine learning for joint disorder detection: Promising advances in diagnostics.","authors":"Zafar Rasheed","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":47093,"journal":{"name":"International Journal of Health Sciences-IJHS","volume":"19 2","pages":"1-3"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yousef M Alharbi, Mohammed Alkhidhr, Hassan Barakat
Objectives: Probiotic-enriched fermented turmeric-camel milk (FTCM) and unfermented (TCM) were examined on streptozotocin (STZ)-induced type 2 diabetes and oxidative stress in rats.
Methods: High phenolics and antioxidant activity were found in TCM and FTCM. FTCM and TCM at 10 or 20 mL/kg were investigated for antidiabetic and hypolipidemic effects in an animal model. The positive group diabetic rats (DR) received 45 mg/kg STZ intraperitoneally; G3 DR (DR+Met) received 50 mg metformin kg-1. G4 (DR+TCM10), G5 (DR+TCM20), G6 (DR+FTCM10), and G7 (DR+FTCM20) received 10 or 20 mL/kg from either TCM or FTCM orally daily, respectively. Blood glucose, liver and kidney functions, antioxidant biomarkers, and histopathology were investigated.
Results: TCM and FTCM had strong phenolics and antioxidant potential. High-performance liquid chromatography analysis quantified ten phenolic acids and four flavonoids, with ferulic acid and resveratrol dominating. TCM and FTCM dramatically decreased random blood glucose and fasting blood glucose. The hypolipidemic effects of TCM and FTCM were more significant at 20 mL/kg than at 10 mL/kg, with substantial reductions in triglycerides, total cholesterol, high- and low-density lipoproteins cholesterol, and very-low-density lipoproteins cholesterol. TCM and FTCM at 20 mL/kg improved liver and kidney functions more than metformin or 10 mL/kg. FTCM and TCM dose-dependently increased antioxidant enzyme activity, glutathione, catalase, and superoxide dismutase, and decreased malondialdehyde. Histopathologically, TCM and FTCM showed typical Langerhans cell and acini structure, outperforming metformin.
Conclusion: TCM and FTCM may help profitably manage diabetes complications and oxidative stress.
{"title":"Antioxidative and ameliorative properties of probiotic-enriched fermented and unfermented turmeric-camel milk in streptozotocin-induced diabetes and oxidative stress in rats.","authors":"Yousef M Alharbi, Mohammed Alkhidhr, Hassan Barakat","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>Probiotic-enriched fermented turmeric-camel milk (FTCM) and unfermented (TCM) were examined on streptozotocin (STZ)-induced type 2 diabetes and oxidative stress in rats.</p><p><strong>Methods: </strong>High phenolics and antioxidant activity were found in TCM and FTCM. FTCM and TCM at 10 or 20 mL/kg were investigated for antidiabetic and hypolipidemic effects in an animal model. The positive group diabetic rats (DR) received 45 mg/kg STZ intraperitoneally; G3 DR (DR+Met) received 50 mg metformin kg<sup>-1</sup>. G4 (DR+TCM10), G5 (DR+TCM20), G6 (DR+FTCM10), and G7 (DR+FTCM20) received 10 or 20 mL/kg from either TCM or FTCM orally daily, respectively. Blood glucose, liver and kidney functions, antioxidant biomarkers, and histopathology were investigated.</p><p><strong>Results: </strong>TCM and FTCM had strong phenolics and antioxidant potential. High-performance liquid chromatography analysis quantified ten phenolic acids and four flavonoids, with ferulic acid and resveratrol dominating. TCM and FTCM dramatically decreased random blood glucose and fasting blood glucose. The hypolipidemic effects of TCM and FTCM were more significant at 20 mL/kg than at 10 mL/kg, with substantial reductions in triglycerides, total cholesterol, high- and low-density lipoproteins cholesterol, and very-low-density lipoproteins cholesterol. TCM and FTCM at 20 mL/kg improved liver and kidney functions more than metformin or 10 mL/kg. FTCM and TCM dose-dependently increased antioxidant enzyme activity, glutathione, catalase, and superoxide dismutase, and decreased malondialdehyde. Histopathologically, TCM and FTCM showed typical Langerhans cell and acini structure, outperforming metformin.</p><p><strong>Conclusion: </strong>TCM and FTCM may help profitably manage diabetes complications and oxidative stress.</p>","PeriodicalId":47093,"journal":{"name":"International Journal of Health Sciences-IJHS","volume":"19 2","pages":"42-56"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Namra Vinay Gohil, Muhammad Ali Muzammil, Ali Shariq, Muhammad Usama Shahid, Merceline Eugène, Muhammad Haseeb, Mohammed Rafea Adnan Shukri, Daniyal Abbasi, Fnu Fariha, Majid Suleman
Objective: This systematic review examines the development and clinical application of hybrid aortic valve interventions that integrate surgical and transcatheter techniques. It focuses on the efficacy, outcomes, and innovations of these procedures, particularly for patients at moderate-to-high surgical risk.
Methods: A comprehensive database search (PubMed, Ovid, Web of Science, Cochrane, CINAHL, Embase, Scopus) was conducted from August 20 to October 10, 2024. Studies on aortic valve interventions combining surgical and transcatheter approaches were included, encompassing case studies, series, cohort studies, and reviews. Non-English articles, gray literature, cadaveric, and animal studies were excluded. Screening followed Preferred Reporting Items for Systematic Review and Meta-Analysis 2023 guidelines, with two rounds performed. Formal quality assessment was omitted due to study heterogeneity.
Results: Out of 2046 initial articles, 495 unique studies remained after duplicate removal, and 65 articles were selected for analysis. Hybrid aortic valve procedures, blending surgical techniques with transcatheter aortic valve implantation, demonstrated improved outcomes, including shorter recovery times, reduced complications, and personalized treatment options for moderate-risk patients.
Conclusion: Hybrid aortic valve interventions mark a significant advancement, enhancing patient-specific care and outcomes. Continued innovation in materials, techniques, and clinician training is crucial to improve durability, long-term outcomes, and broader adoption of these minimally invasive procedures. Future research should address these areas to further optimize cardiovascular care.
目的:本系统综述了结合外科和经导管技术的混合型主动脉瓣介入治疗的发展和临床应用。它着重于这些手术的疗效、结果和创新,特别是对中高手术风险的患者。方法:综合检索PubMed、Ovid、Web of Science、Cochrane、CINAHL、Embase、Scopus等数据库,检索时间为2024年8月20日至10月10日。主动脉瓣介入联合手术和经导管入路的研究包括病例研究、系列研究、队列研究和综述。非英语文章、灰色文献、尸体和动物研究被排除在外。筛选遵循系统评价和荟萃分析2023指南的首选报告项目,进行了两轮筛选。由于研究的异质性,省略了正式的质量评估。结果:在最初的2046篇文章中,去除重复后保留了495篇独特的研究,并选择了65篇文章进行分析。混合主动脉瓣手术,将外科技术与经导管主动脉瓣植入相结合,显示出改善的结果,包括更短的恢复时间,更少的并发症,以及对中等风险患者的个性化治疗选择。结论:混合主动脉瓣介入治疗标志着显著的进步,增强了患者的特异性护理和预后。材料、技术和临床医生培训的持续创新对于提高这些微创手术的耐久性、长期疗效和更广泛的采用至关重要。未来的研究应针对这些领域进一步优化心血管护理。
{"title":"Emerging hybrid techniques in aortic valve interventions: A systematic review of integrating surgical and transcatheter approaches.","authors":"Namra Vinay Gohil, Muhammad Ali Muzammil, Ali Shariq, Muhammad Usama Shahid, Merceline Eugène, Muhammad Haseeb, Mohammed Rafea Adnan Shukri, Daniyal Abbasi, Fnu Fariha, Majid Suleman","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>This systematic review examines the development and clinical application of hybrid aortic valve interventions that integrate surgical and transcatheter techniques. It focuses on the efficacy, outcomes, and innovations of these procedures, particularly for patients at moderate-to-high surgical risk.</p><p><strong>Methods: </strong>A comprehensive database search (PubMed, Ovid, Web of Science, Cochrane, CINAHL, Embase, Scopus) was conducted from August 20 to October 10, 2024. Studies on aortic valve interventions combining surgical and transcatheter approaches were included, encompassing case studies, series, cohort studies, and reviews. Non-English articles, gray literature, cadaveric, and animal studies were excluded. Screening followed Preferred Reporting Items for Systematic Review and Meta-Analysis 2023 guidelines, with two rounds performed. Formal quality assessment was omitted due to study heterogeneity.</p><p><strong>Results: </strong>Out of 2046 initial articles, 495 unique studies remained after duplicate removal, and 65 articles were selected for analysis. Hybrid aortic valve procedures, blending surgical techniques with transcatheter aortic valve implantation, demonstrated improved outcomes, including shorter recovery times, reduced complications, and personalized treatment options for moderate-risk patients.</p><p><strong>Conclusion: </strong>Hybrid aortic valve interventions mark a significant advancement, enhancing patient-specific care and outcomes. Continued innovation in materials, techniques, and clinician training is crucial to improve durability, long-term outcomes, and broader adoption of these minimally invasive procedures. Future research should address these areas to further optimize cardiovascular care.</p>","PeriodicalId":47093,"journal":{"name":"International Journal of Health Sciences-IJHS","volume":"19 2","pages":"66-77"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Gestational diabetes mellitus (GDM) is a prevalent metabolic disorder that adversely affects pregnant women and their growing fetuses. Evidence suggests that genetic and epigenetic modifications, such as DNA methylation, may contribute to the disease phenotype. This study aimed to identify GDM-related hub-methylated genes involved in GDM pathogenesis.
Methods: RNA-seq transcriptomic-wide data (GSE203346) and microarray epigenomic-wide data (GSE106099) were obtained from the Gene Expression Omnibus. Weighted Gene Co-expression Network Analysis (WGCNA) and differential gene expression (DEGs) analysis were performed on the RNA-seq data using the "R" packages "WGCNA" and "DESeq2," respectively. Differentially methylated genes (DMGs) were identified using the "limma" package.
Results: WGCNA identified 18 modules, with only two modules [MEyellow r = -0.32; P = 0.042 and MEmagenta r = -0.32; P = 0.041] showing significant inverse correlations with GDM and one module [MEblue r = 0.35; P = 0.026], showing a direct correlation. Following intersecting the hub genes from WGCNA, DEGs and DMGs, six hub genes were identified as hypomethylated and highly expressed (UCKL1, SHANK2, GDPD5, CMYA5, ESRRG, NOS3), while two genes (DPYSL3 and FTH1) were hypermethylated and showed low expression. Gene set enrichment analysis revealed that the GDM-related hub DMGs were mainly enriched in pathways related to ferroptosis, VEGF signaling, and arginine and proline metabolism.
Conclusion: This multi-omics study identified eight novel GDM-related hub DMGs in placental tissue from GDM cases, suggesting their potential involvement in GDM pathogenesis. Further study is needed.
目的:妊娠期糖尿病(GDM)是一种普遍存在的代谢紊乱,对孕妇及其生长中的胎儿产生不利影响。有证据表明,遗传和表观遗传修饰,如DNA甲基化,可能有助于疾病的表型。本研究旨在确定GDM发病机制中与GDM相关的中心甲基化基因。方法:从Gene Expression Omnibus获得RNA-seq转录组全数据(GSE203346)和微阵列表观基因组全数据(GSE106099)。加权基因共表达网络分析(Weighted Gene Co-expression Network Analysis, WGCNA)和差异基因表达分析(differential Gene expression, DEGs)分别使用“R”软件包“WGCNA”和“DESeq2”对RNA-seq数据进行分析。差异甲基化基因(dmg)鉴定使用“limma”包。结果:WGCNA共鉴定出18个模块,仅鉴定出2个模块[MEyellow r = -0.32;P = 0.042, MEmagenta r = -0.32;P = 0.041]与GDM和一个模块呈显著负相关[MEblue r = 0.35];P = 0.026],显示出直接相关。与WGCNA、DEGs和dmg的枢纽基因相交后,6个枢纽基因被鉴定为低甲基化和高表达(UCKL1、SHANK2、GDPD5、CMYA5、ESRRG、NOS3), 2个枢纽基因(DPYSL3和FTH1)被高甲基化和低表达。基因集富集分析显示,gdm相关枢纽dmg主要富集于与铁下垂、VEGF信号通路、精氨酸和脯氨酸代谢相关的通路。结论:这项多组学研究在GDM患者的胎盘组织中发现了8个新的GDM相关中枢dmg,提示它们可能参与GDM的发病机制。需要进一步的研究。
{"title":"Detection of Novel hub-methylated differentially expressed genes in pregnant women with gestational diabetes mellitus via WGCNA of epigenome-wide and transcriptome-wide profiling.","authors":"Hamdan Z Hamdan","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>Gestational diabetes mellitus (GDM) is a prevalent metabolic disorder that adversely affects pregnant women and their growing fetuses. Evidence suggests that genetic and epigenetic modifications, such as DNA methylation, may contribute to the disease phenotype. This study aimed to identify GDM-related hub-methylated genes involved in GDM pathogenesis.</p><p><strong>Methods: </strong>RNA-seq transcriptomic-wide data (GSE203346) and microarray epigenomic-wide data (GSE106099) were obtained from the Gene Expression Omnibus. Weighted Gene Co-expression Network Analysis (WGCNA) and differential gene expression (DEGs) analysis were performed on the RNA-seq data using the \"R\" packages \"WGCNA\" and \"DESeq2,\" respectively. Differentially methylated genes (DMGs) were identified using the \"limma\" package.</p><p><strong>Results: </strong>WGCNA identified 18 modules, with only two modules [MEyellow r = -0.32; <i>P</i> = 0.042 and MEmagenta r = -0.32; <i>P</i> = 0.041] showing significant inverse correlations with GDM and one module [MEblue r = 0.35; <i>P</i> = 0.026], showing a direct correlation. Following intersecting the hub genes from WGCNA, DEGs and DMGs, six hub genes were identified as hypomethylated and highly expressed (UCKL1, SHANK2, GDPD5, CMYA5, ESRRG, NOS3), while two genes (DPYSL3 and FTH1) were hypermethylated and showed low expression. Gene set enrichment analysis revealed that the GDM-related hub DMGs were mainly enriched in pathways related to ferroptosis, VEGF signaling, and arginine and proline metabolism.</p><p><strong>Conclusion: </strong>This multi-omics study identified eight novel GDM-related hub DMGs in placental tissue from GDM cases, suggesting their potential involvement in GDM pathogenesis. Further study is needed.</p>","PeriodicalId":47093,"journal":{"name":"International Journal of Health Sciences-IJHS","volume":"19 2","pages":"4-16"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maha M Al-Bazi, Abeer A Banjabi, Fares K Khalifa, Bahiya Osrah, Hayat M Albishi, Aliaa M Sabban, Sahar A Alkhodair, Rasha H Hussein
Objectives: The goal of this study was to estimate and compare the prospective therapeutic impacts of different types of bioflavonoids (flavonols, flavanones, and isoflavones) on acute kidney injury (AKI) induced by glycerol in male rats.
Methods: Fifty adult male albino rats (Sprague-Dawley) were separated into five groups: G1, control; G2, rats injected (i.m.) by glycerol (50%) (10 mL/kg b. w.) to induce AKI; G3, G4, and G5, rats received quercetin (QUR), hesperidin (HSP), and genistein (GEN), respectively, after 24 h of glycerol injection for 42 successive days.
Results: Treatment with bioflavonoids improved the renal tissue levels of antioxidant biomarkers (superoxide dismutase, glutathione, catalase, nitric oxide, inflammatory cytokines (interleukin-6, interleukin-1 βeta, nuclear factor kappa-B, tumor necrosis factor-alpha), kidney function markers (creatinine, urea, urine albumin creatinine ratio, albumin) as compared to nephrotoxic groups. QUR extract reduced the serum level of kidney function parameters in glycerol-injected rats more significantly (P ≤ 0.01) than HSP and GEN. Results demonstrated that the GEN as a therapeutic natural agent exhibited the greatest advancement in urine values, followed by the QUR and HSP respectively when compared to the AKI group.
Conclusion: The study results demonstrated the therapeutic effect of bioflavonoids against AKI induced by glycerol. Different types of bioflavonoids could reduce oxidative stress, inhibit the production of inflammatory mediators and cytokines, and improve renal function.
目的:本研究的目的是评估和比较不同类型的生物黄酮(黄酮醇、黄酮和异黄酮)对甘油诱导的雄性大鼠急性肾损伤(AKI)的前瞻性治疗作用。方法:50只成年雄性白化大鼠(Sprague-Dawley)分为5组:G1组,对照组;G2,大鼠ig甘油(50%)(10 mL/kg b. w.)诱导AKI;G3、G4、G5组大鼠注射甘油24 h后,分别给予槲皮素(QUR)、橙皮苷(HSP)、染料木素(GEN),连续42 d。结果:与肾毒性组相比,生物黄酮类药物治疗可改善肾组织抗氧化生物标志物(超氧化物歧化酶、谷胱甘肽、过氧化氢酶、一氧化氮)、炎症因子(白细胞介素-6、白细胞介素-1 β - eta、核因子kappa-B、肿瘤坏死因子α)、肾功能标志物(肌酐、尿素、尿白蛋白、肌酐比、白蛋白)水平。结果表明,与AKI组相比,天然治疗药物GEN对尿值的影响最大,其次是QUR, HSP对尿值的影响最大。结论:生物黄酮类化合物对甘油所致AKI有一定的治疗作用。不同类型的生物黄酮类化合物可降低氧化应激,抑制炎症介质和细胞因子的产生,改善肾功能。
{"title":"The exploration of therapeutic potential of bioflavonoids in metabolic acidosis and inflammation-associated with acute kidney injury: Therapeutic potential of bioflavonoids in acute kidney injury.","authors":"Maha M Al-Bazi, Abeer A Banjabi, Fares K Khalifa, Bahiya Osrah, Hayat M Albishi, Aliaa M Sabban, Sahar A Alkhodair, Rasha H Hussein","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>The goal of this study was to estimate and compare the prospective therapeutic impacts of different types of bioflavonoids (flavonols, flavanones, and isoflavones) on acute kidney injury (AKI) induced by glycerol in male rats.</p><p><strong>Methods: </strong>Fifty adult male albino rats (Sprague-Dawley) were separated into five groups: G1, control; G2, rats injected (i.m.) by glycerol (50%) (10 mL/kg b. w.) to induce AKI; G3, G4, and G5, rats received quercetin (QUR), hesperidin (HSP), and genistein (GEN), respectively, after 24 h of glycerol injection for 42 successive days.</p><p><strong>Results: </strong>Treatment with bioflavonoids improved the renal tissue levels of antioxidant biomarkers (superoxide dismutase, glutathione, catalase, nitric oxide, inflammatory cytokines (interleukin-6, interleukin-1 βeta, nuclear factor kappa-B, tumor necrosis factor-alpha), kidney function markers (creatinine, urea, urine albumin creatinine ratio, albumin) as compared to nephrotoxic groups. QUR extract reduced the serum level of kidney function parameters in glycerol-injected rats more significantly (<i>P</i> ≤ 0.01) than HSP and GEN. Results demonstrated that the GEN as a therapeutic natural agent exhibited the greatest advancement in urine values, followed by the QUR and HSP respectively when compared to the AKI group.</p><p><strong>Conclusion: </strong>The study results demonstrated the therapeutic effect of bioflavonoids against AKI induced by glycerol. Different types of bioflavonoids could reduce oxidative stress, inhibit the production of inflammatory mediators and cytokines, and improve renal function.</p>","PeriodicalId":47093,"journal":{"name":"International Journal of Health Sciences-IJHS","volume":"19 2","pages":"57-65"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Deborah Boluwatife Adeniyi, Nkiru Amala Katchy, Chidera Sandra James-Edeh, Chioma Marylyn Adilieje, David Chibuike Ikwuka, Amechi Uche Katchy, Elvis Shu, Bond Ugochukwu Anyaehie
Objectives: In utero, exposure to maternal high-fat diet (HFD) has been identified to predispose the offspring to obesity and other metabolic dysfunctions later in life. Zingerone, a bioactive phytochemical found in ginger has potential for the treatment of metabolic diseases due to its antioxidant properties. This study investigated its potential reprogramming effect on some metabolic indices and pro-opiomelanocortin (POMC) gene in young adult offspring of Wistar rat models exposed to maternal HFD.
Methods: 30 pregnant Wistar rats were divided into five groups: Normal control group, an HFD control, and three experimental groups treated with 50, 100, or 200 mg/kg of zingerone, respectively. The treatment commenced from day 1 of pregnancy until postnatal day (PND) 21, after which the offsprings were weaned and placed on a standard diet until PND 42. On PND 42, the biochemical assays were performed on the offsprings using enzyme-linked immunosorbent assay kits and the hypothalamic POMC gene expression using reverse transcription polymerase chain reaction. Data were analyzed using analysis of variance. Values of P < 0.05 were taken as statistically significant.
Results: Offsprings in the zingerone-treated groups showed significant (P < 0.05) decrease in body weight, glucose, insulin, cholesterol, triglycerides, and leptin levels compared to the HFD control group. Food intake and ghrelin levels increased, while POMC gene expression was inhibited with 100 and 200 mg/kg of zingerone.
Conclusion: Maternal zingerone administration may mitigate the risk of metabolic disorders in the offspring, possibly by its influence on the anorexigenic genetic makeup of the offspring.
{"title":"Zingerone mitigates metabolic dysfunction and alters pro-opiomelanocortin gene expression in offspring of high-fat diet-fed pregnant wistar rats.","authors":"Deborah Boluwatife Adeniyi, Nkiru Amala Katchy, Chidera Sandra James-Edeh, Chioma Marylyn Adilieje, David Chibuike Ikwuka, Amechi Uche Katchy, Elvis Shu, Bond Ugochukwu Anyaehie","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong><i>In utero</i>, exposure to maternal high-fat diet (HFD) has been identified to predispose the offspring to obesity and other metabolic dysfunctions later in life. Zingerone, a bioactive phytochemical found in ginger has potential for the treatment of metabolic diseases due to its antioxidant properties. This study investigated its potential reprogramming effect on some metabolic indices and pro-opiomelanocortin (POMC) gene in young adult offspring of Wistar rat models exposed to maternal HFD.</p><p><strong>Methods: </strong>30 pregnant Wistar rats were divided into five groups: Normal control group, an HFD control, and three experimental groups treated with 50, 100, or 200 mg/kg of zingerone, respectively. The treatment commenced from day 1 of pregnancy until postnatal day (PND) 21, after which the offsprings were weaned and placed on a standard diet until PND 42. On PND 42, the biochemical assays were performed on the offsprings using enzyme-linked immunosorbent assay kits and the hypothalamic POMC gene expression using reverse transcription polymerase chain reaction. Data were analyzed using analysis of variance. Values of <i>P</i> < 0.05 were taken as statistically significant.</p><p><strong>Results: </strong>Offsprings in the zingerone-treated groups showed significant (<i>P</i> < 0.05) decrease in body weight, glucose, insulin, cholesterol, triglycerides, and leptin levels compared to the HFD control group. Food intake and ghrelin levels increased, while POMC gene expression was inhibited with 100 and 200 mg/kg of zingerone.</p><p><strong>Conclusion: </strong>Maternal zingerone administration may mitigate the risk of metabolic disorders in the offspring, possibly by its influence on the anorexigenic genetic makeup of the offspring.</p>","PeriodicalId":47093,"journal":{"name":"International Journal of Health Sciences-IJHS","volume":"19 2","pages":"17-25"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877057/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ehab M M Ali, Sultan N Sonbul, Eman A Almuhaini, Ayat B Al-Ghafari
Objectives: This study aims to evaluate the synergistic effects of doxorubicin (DOX) and the natural phenolic alkaloid avenanthramide C (AVC) on enhancing apoptosis in MCF-7 breast cancer (BC) cells, with a specific focus on the expression of mitochondrial proteins voltage-dependent anion channel 2 (VDAC2) and mitochondrial carrier homolog 1 (MTCH1) involved in apoptosis pathways.
Methods: MCF-7 cells were treated with various concentrations of DOX and AVC. The 50% inhibitory concentration (IC50) of DOX combined with AVC was evaluated in the MCF-7 cells using an MTT assay, while gene expression levels of Ki-67, MTCH1, and VDAC2 were assessed through real-time polymerase chain reaction. Apoptotic rates were measured using flow cytometry.
Results: DOX and AVC combination reduced the IC50 value by 2.1-fold compared to DOX alone, indicating enhanced cytotoxicity. Co-treatment significantly downregulated Ki-67 expression and increased apoptosis by 76% in cells treated with 3 μM DOX and 160 μM AVC. Gene expression analysis revealed a 4.8-fold increase in MTCH1 and a 15-fold increase in VDAC2 compared to DOX treatment alone.
Conclusion: The DOX-AVC combination demonstrated a potent synergistic effect, enhancing apoptosis in BC cells by modulating mitochondrial pathways. This approach may provide a promising strategy for reducing chemotherapy side effects in BC treatment. Further studies in pre-clinical models are warranted to explore its therapeutic potential.
目的:本研究旨在评估阿霉素(DOX)和天然酚类生物碱avenanthramide C (AVC)在促进MCF-7乳腺癌(BC)细胞凋亡中的协同作用,特别关注参与凋亡途径的线粒体蛋白电压依赖性阴离子通道2 (VDAC2)和线粒体载体同源物1 (MTCH1)的表达。方法:用不同浓度的DOX和AVC处理MCF-7细胞。MTT法测定DOX联合AVC在MCF-7细胞中的50%抑制浓度(IC50),实时聚合酶链反应测定Ki-67、MTCH1和VDAC2的基因表达水平。流式细胞术检测细胞凋亡率。结果:DOX和AVC联合使用比单独使用DOX降低IC50值2.1倍,表明细胞毒性增强。3 μM DOX和160 μM AVC共处理可显著下调Ki-67表达,并使细胞凋亡增加76%。基因表达分析显示,与单独DOX治疗相比,MTCH1增加4.8倍,VDAC2增加15倍。结论:DOX-AVC联合用药可通过调节线粒体通路促进BC细胞凋亡。这种方法可能为减少BC治疗中的化疗副作用提供了一种有希望的策略。临床前模型的进一步研究是必要的,以探索其治疗潜力。
{"title":"Synergetic effect of doxorubicin and avenanthramide C on VDAC2/MTCH1 mitochondrial axis in breast cancer cells.","authors":"Ehab M M Ali, Sultan N Sonbul, Eman A Almuhaini, Ayat B Al-Ghafari","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to evaluate the synergistic effects of doxorubicin (DOX) and the natural phenolic alkaloid avenanthramide C (AVC) on enhancing apoptosis in MCF-7 breast cancer (BC) cells, with a specific focus on the expression of mitochondrial proteins voltage-dependent anion channel 2 (VDAC2) and mitochondrial carrier homolog 1 (MTCH1) involved in apoptosis pathways.</p><p><strong>Methods: </strong>MCF-7 cells were treated with various concentrations of DOX and AVC. The 50% inhibitory concentration (IC<sub>50</sub>) of DOX combined with AVC was evaluated in the MCF-7 cells using an MTT assay, while gene expression levels of <i>Ki-67</i>, <i>MTCH1</i>, and <i>VDAC2</i> were assessed through real-time polymerase chain reaction. Apoptotic rates were measured using flow cytometry.</p><p><strong>Results: </strong>DOX and AVC combination reduced the IC<sub>50</sub> value by 2.1-fold compared to DOX alone, indicating enhanced cytotoxicity. Co-treatment significantly downregulated <i>Ki-67</i> expression and increased apoptosis by 76% in cells treated with 3 μM DOX and 160 μM AVC. Gene expression analysis revealed a 4.8-fold increase in MTCH1 and a 15-fold increase in VDAC2 compared to DOX treatment alone.</p><p><strong>Conclusion: </strong>The DOX-AVC combination demonstrated a potent synergistic effect, enhancing apoptosis in BC cells by modulating mitochondrial pathways. This approach may provide a promising strategy for reducing chemotherapy side effects in BC treatment. Further studies in pre-clinical models are warranted to explore its therapeutic potential.</p>","PeriodicalId":47093,"journal":{"name":"International Journal of Health Sciences-IJHS","volume":"19 2","pages":"26-41"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sharmila Patil, Manjyot Gautam, Divya Shetty, Surekha Bhalekar, S Sudhamani
Granulomatous mycosis fungoides (GMF) is a rare subtype of T-cell cutaneous lymphoma. Due to the lack of distinct clinical features, GMF may pose a diagnostic challenge, which results in diagnostic delay. The diagnosis is based on histopathological and immunohistochemical findings. Herein, we present an 82-year-old male with itchy lesions over the scalp, face, forearms, trunk, and bilateral lower limbs for 6 months. Histologically, it was a CD8-positive GMF. GMF is a rare subtype of mycosis fungoides with <100 cases in the literature, and most of these cases showed a CD4-positive phenotype. CD8-positive GMF is extremely rare. We observed that it commonly affects elderly females. The patients often present with nodules and do not carry an adverse prognosis.
{"title":"Primary cutaneous CD8-positive T-cell lymphoma-granulomatous mycosis fungoides: A rare case report.","authors":"Sharmila Patil, Manjyot Gautam, Divya Shetty, Surekha Bhalekar, S Sudhamani","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Granulomatous mycosis fungoides (GMF) is a rare subtype of T-cell cutaneous lymphoma. Due to the lack of distinct clinical features, GMF may pose a diagnostic challenge, which results in diagnostic delay. The diagnosis is based on histopathological and immunohistochemical findings. Herein, we present an 82-year-old male with itchy lesions over the scalp, face, forearms, trunk, and bilateral lower limbs for 6 months. Histologically, it was a CD8-positive GMF. GMF is a rare subtype of mycosis fungoides with <100 cases in the literature, and most of these cases showed a CD4-positive phenotype. CD8-positive GMF is extremely rare. We observed that it commonly affects elderly females. The patients often present with nodules and do not carry an adverse prognosis.</p>","PeriodicalId":47093,"journal":{"name":"International Journal of Health Sciences-IJHS","volume":"19 2","pages":"78-81"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sayed Abdulla Jami, Abdulkader Helwan, Tamima Tarin, Mosammad Aysha, Siam Al Mobarak
Objectives: This study aims to assess the correlation between clinical features and mortality in human immunodeficiency virus (HIV)-infected individuals with COVID-19.
Methods: A systematic literature search was conducted for cohort, cross-sectional, and case series that reported co-infection with HIV and COVID-19 published from January to September 2020. Clinical features such as age, comorbidities, CD4+T lymphocyte counts, HIV RNA levels, and antiretroviral regimens were evaluated using meta-analyses and systematic reviews. Meta-analysis was performed using Stata 15.0 software.
Results: A total of 24 articles with 939 cases of HIV/COVID-19 co-infection were included in this study. The overall mortality rate was 10.3% (97/939). Older age and comorbidities including hypertension, diabetes, renal insufficiency, chronic obstructive pulmonary disease/asthma, and tumors were significantly associated with increased mortality (95% confidence interval 0.005-0.050, 0.042-2.294, 0.390-2.754, 0.513-2.848, 0.348-3.743, and 1.943-7.101, respectively, P = 0.021, 0.043, 0.012, 0.008, 0.022, and 0.005). There was no significant correlation between mortality and CD4+T lymphocyte count <200/μL or >500/μL, HIV RNA level below the detection limit, or antiretroviral drugs (including tenofovir) (all P > 0.05). Improved HIV treatment, complex immune interactions, study population variability, and lack of direct SARS-CoV-2 targeting by ART likely obscure the correlation between CD4+ counts or ART and COVID-19 mortality in HIV patients.
Conclusion: HIV-infected individuals with COVID-19 have a similar prognosis to the general population. However, older age, comorbidities (hypertension and diabetesetc.), and lower CD4+ T-cell counts are associated with increased mortality. Mainstream anti-HIV drugs do not offer significant protection against COVID-19.
{"title":"Factors affecting poor prognosis of COVID-19 in people living with human immunodeficiency virus: A systematic review and meta-analysis of co-infection.","authors":"Sayed Abdulla Jami, Abdulkader Helwan, Tamima Tarin, Mosammad Aysha, Siam Al Mobarak","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to assess the correlation between clinical features and mortality in human immunodeficiency virus (HIV)-infected individuals with COVID-19.</p><p><strong>Methods: </strong>A systematic literature search was conducted for cohort, cross-sectional, and case series that reported co-infection with HIV and COVID-19 published from January to September 2020. Clinical features such as age, comorbidities, CD4<sup>+</sup>T lymphocyte counts, HIV RNA levels, and antiretroviral regimens were evaluated using meta-analyses and systematic reviews. Meta-analysis was performed using Stata 15.0 software.</p><p><strong>Results: </strong>A total of 24 articles with 939 cases of HIV/COVID-19 co-infection were included in this study. The overall mortality rate was 10.3% (97/939). Older age and comorbidities including hypertension, diabetes, renal insufficiency, chronic obstructive pulmonary disease/asthma, and tumors were significantly associated with increased mortality (95% confidence interval 0.005-0.050, 0.042-2.294, 0.390-2.754, 0.513-2.848, 0.348-3.743, and 1.943-7.101, respectively, <i>P</i> = 0.021, 0.043, 0.012, 0.008, 0.022, and 0.005). There was no significant correlation between mortality and CD4<sup>+</sup>T lymphocyte count <200/μL or >500/μL, HIV RNA level below the detection limit, or antiretroviral drugs (including tenofovir) (all <i>P</i> > 0.05). Improved HIV treatment, complex immune interactions, study population variability, and lack of direct SARS-CoV-2 targeting by ART likely obscure the correlation between CD4<sup>+</sup> counts or ART and COVID-19 mortality in HIV patients.</p><p><strong>Conclusion: </strong>HIV-infected individuals with COVID-19 have a similar prognosis to the general population. However, older age, comorbidities (hypertension and diabetesetc.), and lower CD4<sup>+</sup> T-cell counts are associated with increased mortality. Mainstream anti-HIV drugs do not offer significant protection against COVID-19.</p>","PeriodicalId":47093,"journal":{"name":"International Journal of Health Sciences-IJHS","volume":"19 1","pages":"49-55"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zakia A Abu-Zahab, Hina Qureshi, Gihan M Adham, Wafaa M Elzefzafy, Sahar S Zalam, Abeer M Rehan, Manal F Abdelhameed, Amany A Bayoumy, Sinna K AlKarkosh, Waad G Fakhouri, Ahmed Y Sharfi, Salwa A Alkhawaga, Lamaa M El-Attar, Sahar S Amin, Ranin A Alrefaei
Objectives: Vitamin B12 (Cobalamin or Cbl) plays a crucial role in normal human growth and development, as well as in neurological, cardiovascular, and immune systems. Previous studies reported association of high levels of cobalamin with solid cancers, hematological disorders, and liver diseases. Reporting the frequency of comorbid diseases with high serum Vitamin B12 level in patients attending KSAMC at Madinah.
Methods: This is a retrospective, cross-sectional study on data collected during 1 year (May 2022-May 2023) from 3511 report, patients with high cobalamin blood level (normal upper limit 771 pg/mL) as determined in our laboratory on COBAS® were included. Patient's clinical diagnosis, medication history and other laboratory parameters performed were also checked for disease comorbidities.
Results: Our results revealed statistically significant increase in serum Vitamin B12 in patients with diabetes mellitus, with the use of this vitamin as supplement therapy 53.2% (the predominant comorbidity), together with liver, blood, chest, kidney, thyroid and neurological diseases, and various solid tumors. A positive correlation was found between serum Vitamin B12, age and laboratory parameters including aspartate aminotransferase, gamma-glutamyl transferase, and direct bilirubin, and a negative correlation was seen between serum Vitamin B12 level, serum albumin (ALB), red blood cell count, hemoglobin, and free T3 (FT3). While, no significant correlation with the rest of the checked parameters was detected.
Conclusion: This study found high serum level of Vitamin B12 associated with various disease entities, for example, (diabetes mellitus treated with Vitamin B12 as supplement therapy, liver, blood, chest, kidney, thyroid, neurological diseases, and various solid tumors), so when Vitamin B12 is high, further investigations will be recommended. Most of the comorbidities were benign in Saudis, followed by Egyptians with predominance of female-aged 50-70 year old.
{"title":"Frequency of comorbid diseases with high serum Vitamin B12 levels in patients attending King Salman Medical City (KSAMC), at Madinah.","authors":"Zakia A Abu-Zahab, Hina Qureshi, Gihan M Adham, Wafaa M Elzefzafy, Sahar S Zalam, Abeer M Rehan, Manal F Abdelhameed, Amany A Bayoumy, Sinna K AlKarkosh, Waad G Fakhouri, Ahmed Y Sharfi, Salwa A Alkhawaga, Lamaa M El-Attar, Sahar S Amin, Ranin A Alrefaei","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>Vitamin B12 (Cobalamin or Cbl) plays a crucial role in normal human growth and development, as well as in neurological, cardiovascular, and immune systems. Previous studies reported association of high levels of cobalamin with solid cancers, hematological disorders, and liver diseases. Reporting the frequency of comorbid diseases with high serum Vitamin B12 level in patients attending KSAMC at Madinah.</p><p><strong>Methods: </strong>This is a retrospective, cross-sectional study on data collected during 1 year (May 2022-May 2023) from 3511 report, patients with high cobalamin blood level (normal upper limit 771 pg/mL) as determined in our laboratory on COBAS<sup>®</sup> were included. Patient's clinical diagnosis, medication history and other laboratory parameters performed were also checked for disease comorbidities.</p><p><strong>Results: </strong>Our results revealed statistically significant increase in serum Vitamin B12 in patients with diabetes mellitus, with the use of this vitamin as supplement therapy 53.2% (the predominant comorbidity), together with liver, blood, chest, kidney, thyroid and neurological diseases, and various solid tumors. A positive correlation was found between serum Vitamin B12, age and laboratory parameters including aspartate aminotransferase, gamma-glutamyl transferase, and direct bilirubin, and a negative correlation was seen between serum Vitamin B12 level, serum albumin (ALB), red blood cell count, hemoglobin, and free T3 (FT3). While, no significant correlation with the rest of the checked parameters was detected.</p><p><strong>Conclusion: </strong>This study found high serum level of Vitamin B12 associated with various disease entities, for example, (diabetes mellitus treated with Vitamin B12 as supplement therapy, liver, blood, chest, kidney, thyroid, neurological diseases, and various solid tumors), so when Vitamin B12 is high, further investigations will be recommended. Most of the comorbidities were benign in Saudis, followed by Egyptians with predominance of female-aged 50-70 year old.</p>","PeriodicalId":47093,"journal":{"name":"International Journal of Health Sciences-IJHS","volume":"19 1","pages":"15-21"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}